Villante receives retroactive TUE exemption

February 25, 2017

UFC light heavyweight Gian Villante was issued a retroactive therapeutic use exemption by USADA which clears him of a potential anti-doping violation.

Via USADA release:

Villante, 31, declared the use of a Breo Ellipta (fluticasone furoate/vilanterol) inhaler during an out-of-competition urine test conducted on January 18, 2017, and subsequently tested positive for vilanterol. Vilanterol is a prohibited substance in the category of Beta-2 Agonists and is prohibited at all times under the UFC Anti-Doping Policy, which has adopted the World Anti-Doping Agency (WADA) Prohibited List.

Following his disclosure, USADA advised Villante that absent a valid TUE, the use of the inhaler was prohibited under the UFC Anti-Doping Policy. Thereafter, Villante submitted a TUE application documenting that his physician prescribed a 14-day course of the inhaler to treat conditions associated with airflow restriction and asthma.

Notably, the same day that Villante was granted the TUE exemption, Tom Lawlor, who beat Villante, agreed to a two-year suspension.

Payout Perspective:

Villante’s reasons for the retroactive TUE is the purpose of the retroactive exemption.  From the story, it sounds as though he did what he was supposed to do in declaring the use of the prohibited substance and followed up with the physician prescription and application for the retroactive TUE.  Obviously, the best practice may have been to contact USADA ahead of time for the exemption rather than apply retroactively.

Got something to say?